91374-20-8 | Ropinirole HCl

Packsize	Purity	Availability	Price	Discounted Price
1mg	99%	in stock	$7.00	$5.00
25mg	99%	in stock	$26.00	$18.00
50mg	99%	in stock	$41.00	$29.00
250mg	99%	in stock	$84.00	$59.00
1g	99%	in stock	$209.00	$146.00

Description

• Catalog Number: AC94800
• Chemical Name: Ropinirole HCl
• CAS Number: 91374-20-8
• Molecular Formula: C16H25ClN2O
• Molecular Weight: 296.8355
• MDL Number: MFCD01754173
• SMILES: CCCN(CCC)CCc1cccc2c1CC(=O)N2.Cl

Computed Properties

• Complexity: 287
• Covalently-Bonded Unit Count: 2
• Heavy Atom Count: 20
• Hydrogen Bond Acceptor Count: 2
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 7

Literature

• Ceftriaxone mediated rescue of nigral oxidative damage and motor deficits in MPTP model of Parkinson's disease in rats.

  Neurotoxicology 20140901

• Pharmacokinetics and effect of food after oral administration of prolonged-release tablets of ropinirole hydrochloride in Japanese patients with Parkinson's disease.

  Journal of clinical pharmacy and therapeutics 20121001

• ADMET considerations for restless leg syndrome drug treatments.

  Expert opinion on drug metabolism & toxicology 20121001

• A fatal intoxication case involving ropinirole.

  Journal of forensic and legal medicine 20121001

• Ropinirole as an effective adjunctive treatment for clozapine-resistant negative symptoms in simple schizophrenia: a case report.

  Journal of clinical psychopharmacology 20121001

• Assessment of ropinirole as a reinforcer in rhesus monkeys.

  Drug and alcohol dependence 20120901

• Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease.

  Neurobiology of disease 20120901

• Spontaneous unwelcome orgasms due to pramipexole and ropinirole.

  Movement disorders : official journal of the Movement Disorder Society 20120901

• The treatment of restless legs syndrome and periodic limb movement disorder in adults--an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline.

  Sleep 20120801

• Literature based drug interaction prediction with clinical assessment using electronic medical records: novel myopathy associated drug interactions.

  PLoS computational biology 20120801

• Indirect comparisons of adverse events and dropout rates in early Parkinson's disease trials of pramipexole, ropinirole, and rasagiline.

  The International journal of neuroscience 20120701

• Myometry revealed medication-induced decrease in resting skeletal muscle stiffness in Parkinson's disease patients.

  Clinical biomechanics (Bristol, Avon) 20120701

• Structure-activity relationship study of N⁶-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N⁶-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine analogues: development of highly selective D3 dopamine receptor agonists along with a highly potent D2/D3 agonist and their pharmacological characterization.

  Journal of medicinal chemistry 20120628

• New prospective in treatment of Parkinson's disease: studies on permeation of ropinirole through buccal mucosa.

  International journal of pharmaceutics 20120615

• The effect of ropinirole on apathy and depression after herpes encephalitis.

  Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology 20120601

• Use of spectroscopic, zeta potential and molecular dynamic techniques to study the interaction between human holo-transferrin and two antagonist drugs: comparison of binary and ternary systems.

  Molecules (Basel, Switzerland) 20120312

• Breakthrough symptoms during the daytime in patients with restless legs syndrome (Willis-Ekbom disease).

  Sleep medicine 20120201

• Clinical inquiry. Which drugs work best for early Parkinson's disease?

  The Journal of family practice 20120201

• Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis-Ekbom disease): results from a prospective, multicenter study over 66 weeks.

  Movement disorders : official journal of the Movement Disorder Society 20120201

• Oil based nanocarrier system for transdermal delivery of ropinirole: a mechanistic, pharmacokinetic and biochemical investigation.

  International journal of pharmaceutics 20120117

• Improvements in nocturnal symptoms with ropinirole prolonged release in patients with advanced Parkinson's disease.

  European journal of neurology 20120101

• Investigating variability in patient response to treatment--a case study from a replicate cross-over study.

  Statistical methods in medical research 20111201

• Sustained release microspheres of ropinirole hydrochloride: effect of process parameters.

  Acta pharmaceutica (Zagreb, Croatia) 20111201

• Dopamine-deficiency-enhanced hyperthermia and rhabdomyolysis during a heat wave in a metachromatic leucodystrophy heterozygote with metabolic myopathy.

  Acta neurologica Belgica 20111201

• Evaluation of antidepressant activity of ropinirole coadministered with fluoxetine in acute and chronic behavioral models of depression in rats.

  Journal of basic and clinical physiology and pharmacology 20111122

• Effect of chronic kidney disease on excessive daytime sleepiness in Parkinson disease.

  European journal of neurology 20111101

• Acupuncture for restless legs syndrome in patients previously treated with dopaminergic drugs.

  Acupuncture in medicine : journal of the British Medical Acupuncture Society 20110901

• Severe intracranial bleeding related to vitamin K antagonist-ropinirole interaction.

  Movement disorders : official journal of the Movement Disorder Society 20110815

• [Pathological gambling induced by dopamine agonists].

  Fortschritte der Neurologie-Psychiatrie 20110801

• Pathological behaviors provoked by dopamine agonist therapy of Parkinson's disease.

  Physiology & behavior 20110725

• Ropinirole improves depressive symptoms and restless legs syndrome severity in RLS patients: a multicentre, randomized, placebo-controlled study.

  Journal of neurology 20110601

• Liver toxicity possibly related with ropinirole use in the treatment of restless legs syndrome.

  European journal of neurology 20110601

• PREPARED: Comparison of prolonged and immediate release ropinirole in advanced Parkinson's disease.

  Movement disorders : official journal of the Movement Disorder Society 20110601

• Long-term, open-label study of once-daily ropinirole prolonged release in early Parkinson's disease.

  The International journal of neuroscience 20110501

• Dopamine agonist-triggered pathological behaviors: surveillance in the PD clinic reveals high frequencies.

  Parkinsonism & related disorders 20110501

• Restless legs syndrome (RLS) augmentation associated with dopamine agonist and levodopa usage in a community sample.

  Sleep medicine 20110501

• Pramipexole versus ropinirole: polysomnographic acute effects in restless legs syndrome.

  Movement disorders : official journal of the Movement Disorder Society 20110401

• cAMP response element binding protein phosphorylation in nucleus accumbens underlies sustained recovery of sensorimotor gating following repeated D₂-like receptor agonist treatment in rats.

  Biological psychiatry 20110201

• Mirtazapine-induced worsening of restless legs syndrome (RLS) and ropinirole-induced psychosis: challenges in management of depression in RLS.

  Psychosomatics 20110101

• Impulsive cross-dressing in Parkinson's disease treated with ropinerole.

  The Journal of neuropsychiatry and clinical neurosciences 20110101

• Safety, tolerability, and self-rated effects of aripiprazole and ropinirole treatment for cocaine dependence: a pilot study.

  The American journal on addictions 20110101

• Aripiprazole and ropinirole treatment for cocaine dependence: evidence from a pilot study.

  Current pharmaceutical design 20110101

• Agonist-specific voltage sensitivity at the dopamine D2S receptor--molecular determinants and relevance to therapeutic ligands.

  Neuropharmacology 20110101

• Overnight switch from ropinirole to transdermal rotigotine patch in patients with Parkinson disease.

  BMC neurology 20110101

• Dopaminergic drug-induced modulation of the expression of the dopamine transporter in peripheral blood lymphocytes in Parkinson's disease.

  Pharmacological reports : PR 20110101

• Evaluating the effects of crystallinity in new biocompatible polyester nanocarriers on drug release behavior.

  International journal of nanomedicine 20110101

• 'You never told me I would turn into a gambler': a first person account of dopamine agonist--induced gambling addiction in a patient with restless legs syndrome.

  BMJ case reports 20110101

• Nanoencapsulation of a water soluble drug in biocompatible polyesters. Effect of polyesters melting point and glass transition temperature on drug release behavior.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20101223

• Facile synthesis of polyester-PEG triblock copolymers and preparation of amphiphilic nanoparticles as drug carriers.

  Journal of controlled release : official journal of the Controlled Release Society 20101220

• An anti-Parkinson drug ropinirole depletes orexin from rat hypothalamic slice culture.

  Neuroscience research 20101201

• Pre-treatment with dopamine agonists influence L-dopa mediated rotations without affecting abnormal involuntary movements in the 6-OHDA lesioned rat.

  Behavioural brain research 20101112

• Monitoring dyskinesia with Zif.

  Experimental neurology 20101101

• Inflammatory aneurysm of the abdominal aorta in a patient treated with ropinirole.

  Journal of neurology 20100901

• Isolated delusional syndrome in Parkinson's Disease.

  Parkinsonism & related disorders 20100901

• Effects of ropinirole on action potential characteristics and the underlying ion currents in canine ventricular myocytes.

  Naunyn-Schmiedeberg's archives of pharmacology 20100901

• Dyskinetic potential of dopamine agonists is associated with different striatonigral/striatopallidal zif-268 expression.

  Experimental neurology 20100801

• Rare and serious cardiac side effects during ropinirole titration.

  Movement disorders : official journal of the Movement Disorder Society 20100730

• Progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) with fatal outcome, after the manifestation of an ampullary adenocarcinoma.

  Pancreas 20100701

• Effects of ropinirole prolonged-release on sleep disturbances and daytime sleepiness in Parkinson disease.

  Clinical neuropharmacology 20100701

• Successful treatment of post-stroke apathy by the dopamine receptor agonist ropinirole.

  Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 20100601

• Ropinirole augmentation therapy in a case with treatment-resistant unipolar depression.

  Progress in neuro-psychopharmacology & biological psychiatry 20100530

• Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease.

  Movement disorders : official journal of the Movement Disorder Society 20100515

• Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations.

  Movement disorders : official journal of the Movement Disorder Society 20100515

• Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients.

  Archives of neurology 20100501

• The effect of dopamine agonists: the expression of GDNF, NGF, and BDNF in cultured mouse astrocytes.

  Journal of the neurological sciences 20100415

• Formulation of intranasal mucoadhesive temperature-mediated in situ gel containing ropinirole and evaluation of brain targeting efficiency in rats.

  Journal of drug targeting 20100401

• Comparative placebo-controlled polysomnographic and psychometric studies on the acute effects of gabapentin versus ropinirole in restless legs syndrome.

  Journal of neural transmission (Vienna, Austria : 1996) 20100401

• Impulsive smoking in a patient with Parkinson's disease treated with dopamine agonists.

  Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 20100401

• Ropinirole diminishes myoclonus and improves writing and postural balance in an ULD patient.

  Movement disorders : official journal of the Movement Disorder Society 20100315

• [Clinical data of the prolonged-release formulation of ropinirole].

  Fortschritte der Neurologie-Psychiatrie 20100301

• Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials.

  Drug safety 20100201

• Sustained dopaminergic response of parkinsonism and depression in POLG-associated parkinsonism.

  Movement disorders : official journal of the Movement Disorder Society 20100130

• Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects.

  Clinical neuropharmacology 20100101

• Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study.

  Sleep 20100101

• The dopamine-D2-receptor agonist ropinirole dose-dependently blocks the Ca2+-triggered permeability transition of mitochondria.

  Biochimica et biophysica acta 20100101

• Impact of dopamine agonists on compulsive behaviors: a case series of pramipexole-induced pathological gambling.

  Psychosomatics 20100101

• Nonmotor symptoms in de novo Parkinson disease before and after dopaminergic treatment.

  Journal of the neurological sciences 20091215

• Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson's disease.

  European journal of clinical pharmacology 20091201

• Nanocarrier for the transdermal delivery of an antiparkinsonian drug.

  AAPS PharmSciTech 20091201

• Long half-life and prolonged-release dopamine receptor agonists: a review of ropinirole prolonged-release studies.

  Parkinsonism & related disorders 20091201

• A multicentre retrospective study of the clinical use of ropinirole in the treatment of Parkinson's disease: the ROPI-PARK study.

  Clinical neurology and neurosurgery 20091101

• An open-label conversion study of pramipexole to ropinirole prolonged release in Parkinson's disease.

  Movement disorders : official journal of the Movement Disorder Society 20091030

• Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.

  Nature chemical biology 20091001

• Critical review of ropinirole and pramipexole - putative dopamine D(3)-receptor selective agonists - for the treatment of RLS.

  Journal of clinical pharmacy and therapeutics 20091001

• Reward-learning and the novelty-seeking personality: a between- and within-subjects study of the effects of dopamine agonists on young Parkinson's patients.

  Brain : a journal of neurology 20090901

• Randomized, placebo-controlled, double-blind study of ropinirole in chronic stroke.

  Stroke 20090901

• An exploratory retrospective evaluation of ropinirole-associated psychotic symptoms in an outpatient population treated for restless legs syndrome or Parkinson's disease.

  The Annals of pharmacotherapy 20090901

• Agonist or levodopa for Parkinson disease? Ultimately, it doesn't matter; neither is good enough.

  Neurology 20090616

• [Socioeconomic relevance of the idiopathic restless legs syndrome (RLS) in Germany: cost-of-illness study].

  Medizinische Klinik (Munich, Germany : 1983) 20090515

• Dose-dependent inverted U-shaped effect of dopamine (D2-like) receptor activation on focal and nonfocal plasticity in humans.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20090513

• Psychometric evaluation and tests of validity of the Medical Outcomes Study 12-item Sleep Scale (MOS sleep).

  Sleep medicine 20090501

• Highly sensitive method for the determination of ropinirole with a lower limit of quantitation of 3.45 pg/mL in human plasma by LC-ESI-MS/MS: application to a clinical pharmacokinetic study.

  Biomedical chromatography : BMC 20090501

• Bilateral restless legs affecting a phantom limb, treated with dopamine agonists.

  Journal of neurology, neurosurgery, and psychiatry 20090501

• Frequency of new-onset pathologic compulsive gambling or hypersexuality after drug treatment of idiopathic Parkinson disease.

  Mayo Clinic proceedings 20090401

• Nanoemulsion components screening and selection: a technical note.

  AAPS PharmSciTech 20090301

• Unilateral RLS with predominantly ipsilateral PLMS and variable response to dopaminergic drugs: a variant of idiopathic RLS?

  European journal of neurology 20090301

• Effect of ropinirole on sleep outcomes in patients with restless legs syndrome: meta-analysis of pooled individual patient data from randomized controlled trials.

  Pharmacotherapy 20090301

• Treatment options for restless legs syndrome.

  Expert opinion on pharmacotherapy 20090301

• Chemometrical evaluation of ropinirole and its impurity's chromatographic behavior.

  Journal of chromatography. A 20090220

• Effectiveness of ropinirole for RLS and depressive symptoms in an 11-year-old girl.

  Sleep medicine 20090201

• [Impulse control disorder induced by the use of dopamine agonists].

  Nederlands tijdschrift voor geneeskunde 20090117

• Punding in patients on dopamine agonists for restless leg syndrome.

  Movement disorders : official journal of the Movement Disorder Society 20090115

• Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists.

  Movement disorders : official journal of the Movement Disorder Society 20090115

• Pharmacokinetic and pharmacodynamic comparison of ropinirole 24-hour prolonged release and ropinirole immediate release in patients with Parkinson's disease.

  Clinical neuropharmacology 20090101

• Ropinirole prolonged release: in advanced Parkinson's disease.

  CNS drugs 20090101

• Range of drugs associated with IFIS.

  Journal of cataract and refractive surgery 20090101

• A review of ropinirole prolonged release in Parkinson's disease.

  Clinical interventions in aging 20090101

• Panic attack-like episodes possibly associated with ropinirole.

  Clinical neuropharmacology 20090101

• Clinical efficacy of ropinirole for restless legs syndrome is not affected by age at symptom onset.

  Sleep medicine 20081201

• Restless legs syndrome caused by quetiapine successfully treated with ropinirole in 2 patients with bipolar disorder.

  Journal of clinical psychopharmacology 20081201

• Restless leg syndrome, dopamine agonists and sleep attacks.

  Internal medicine journal 20081101

• [Treatment of Parkinson's disease at present and in the future].

  Rinsho shinkeigaku = Clinical neurology 20081101

• [Sleep disorders in adults].

  La Revue du praticien 20081031

• Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome.

  Sleep medicine 20081001

• Discontinuation of ropinirole and pramipexole in patients with Parkinson's disease: clinical practice versus clinical trials.

  European journal of clinical pharmacology 20081001

• Heart valve abnormalities in Parkinson's disease treated with dopamine agonists.

  Journal of neurology 20081001

• Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, double-blind, non-inferiority crossover study.

  Current medical research and opinion 20081001

• Cost-effectiveness of licensed treatment options for restless legs syndrome in the UK and Sweden.

  Current medical research and opinion 20081001

• Initial experience with ropinirole PR (prolonged release).

  Journal of neurology 20080901

• Rapid resolution of dopamine dysregulation syndrome (DDS) after subthalamic DBS for Parkinson disease (PD): a case report.

  Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology 20080901

• Adverse effects of ropinirole-treated restless leg syndrome (RLS) during smoking cessation.

  Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 20080815

• Response to ropinirole in restless legs syndrome is independent of baseline serum ferritin.

  Journal of neurology, neurosurgery, and psychiatry 20080801

• Ropinirole-induced symptomatic sinus node dysfunction.

  Pacing and clinical electrophysiology : PACE 20080801

• Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat.

  Synapse (New York, N.Y.) 20080701

• Highly sensitive and selective spectrophotometric and spectrofluorimetric methods for the determination of ropinirole hydrochloride in tablets.

  Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy 20080601

• Internal medicine: guidance to the diagnosis and management of restless legs syndrome.

  Southern medical journal 20080601

• Restless legs syndrome in women: a review.

  Journal of women's health (2002) 20080601

• Differential modulation of Akt/glycogen synthase kinase-3beta pathway regulates apoptotic and cytoprotective signaling responses.

  The Journal of biological chemistry 20080530

• A case of transient hallucination with ropinirole augmentation antidepressant in a patient with treatment-resistant depression: Is there differential effect of ropinirole dose on developing psychotic symptom?

  Progress in neuro-psychopharmacology & biological psychiatry 20080515

• Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive symptom.

  Movement disorders : official journal of the Movement Disorder Society 20080515

• Continuous delivery of ropinirole reverses motor deficits without dyskinesia induction in MPTP-treated common marmosets.

  Experimental neurology 20080501

• Relationship between weight, levodopa and dyskinesia: the significance of levodopa dose per kilogram body weight.

  European journal of neurology 20080501

• Appropriate use of dopamine agonists and levodopa in restless legs syndrome in an ambulatory care setting.

  The Annals of pharmacotherapy 20080501

• Ropinirole treatment for restless legs syndrome.

  Expert opinion on drug metabolism & toxicology 20080501

• Study of the applicabilty of content uniformity and dissolution variation test on ropinirole hydrochloride tablets.

  Bosnian journal of basic medical sciences 20080501

• D2/D3 receptor agonist ropinirole protects dopaminergic cell line against rotenone-induced apoptosis through inhibition of caspase- and JNK-dependent pathways.

  FEBS letters 20080305

• Ropinirole treatment for restless legs syndrome.

  Expert opinion on pharmacotherapy 20080301

• Restless legs syndrome in older adults.

  Clinics in geriatric medicine 20080201

• Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease.

  Clinical neuropharmacology 20080101

• A pilot open-label trial of ropinirole for cocaine dependence.

  The American journal on addictions 20080101

• Side effects of ropinirole in patients with idiopathic Parkinson's disease.

  Bratislavske lekarske listy 20080101

• Effects of ropinirole on nonmotor symptoms of Parkinson disease: a prospective multicenter study.

  Clinical neuropharmacology 20080101

• Patient- and physician-rated measures demonstrate the effectiveness of ropinirole in the treatment of restless legs syndrome.

  Clinical neuropharmacology 20080101

• [Systemic review and meta-analysis of tolerability and safety between different titration regimes of ropinirol dose in the treatment of Parkinson's disease].

  Neurologia (Barcelona, Spain) 20071201

• Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa.

  Movement disorders : official journal of the Movement Disorder Society 20071201

• Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole.

  Movement disorders : official journal of the Movement Disorder Society 20071201

• The administration of entacapone prevents L-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primates.

  Experimental neurology 20071201

• Steady-state pharmacokinetic properties of a 24-hour prolonged-release formulation of ropinirole: results of two randomized studies in patients with Parkinson's disease.

  Clinical therapeutics 20071201

• A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome.

  Sleep medicine 20071101

• A case of aripiprazole-related tardive akathisia and its treatment with ropinirole.

  The Journal of clinical psychiatry 20071101

• Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study.

  Movement disorders : official journal of the Movement Disorder Society 20071015

• Disruption of prepulse inhibition of the startle reflex by the preferential D(3) agonist ropinirole in healthy males.

  Psychopharmacology 20071001

• Restless legs syndrome: nonpharmacologic and pharmacologic treatments.

  Geriatrics 20071001

• [Pharmacological profiles and clinical effects of ropinirole hydrochloride (ReQuip)].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20071001

• Involvement of dopamine (DA)/serotonin (5-HT)/sigma (sigma) receptor modulation in mediating the antidepressant action of ropinirole hydrochloride, a D2/D3 dopamine receptor agonist.

  Brain research bulletin 20070914

• Overexpression of D2/D3 receptors increases efficacy of ropinirole in chronically 6-OHDA-lesioned Parkinsonian rats.

  Brain research 20070730

• Locomotion is increased in a11-lesioned mice with iron deprivation: a possible animal model for restless legs syndrome.

  Journal of neuropathology and experimental neurology 20070501

• Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease.

  Neurology 20070403

• Identification of amino acid determinants of dopamine 2 receptor synthetic agonist function.

  The Journal of pharmacology and experimental therapeutics 20070401

• Spectrophotometric determination of dopaminergic drugs used for Parkinson's disease, cabergoline and ropinirole, in pharmaceutical preparations.

  Chemical & pharmaceutical bulletin 20070401

• [Improvements in motor and non-motor symptoms in parkinson patients under ropinirole therapy].

  Fortschritte der Neurologie-Psychiatrie 20070401

• Sumanirole versus placebo or ropinirole for the adjunctive treatment of patients with advanced Parkinson's disease.

  Movement disorders : official journal of the Movement Disorder Society 20070315

• A comparison of sumanirole versus placebo or ropinirole for the treatment of patients with early Parkinson's disease.

  Movement disorders : official journal of the Movement Disorder Society 20070315

• Isolation and characterization of some potential impurities in ropinirole hydrochloride.

  Journal of pharmaceutical and biomedical analysis 20070312

• Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets.

  Experimental neurology 20070301

• Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease.

  Archives of neurology 20070301

• [Placebo effect in Parkinson's disease].

  No to shinkei = Brain and nerve 20070201

• The effect of Madopar on the pharmacokinetics of ropinirole in healthy Chinese volunteers.

  Journal of pharmaceutical and biomedical analysis 20070117

• Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study.

  Movement disorders : official journal of the Movement Disorder Society 20070115

• [Dopamine agonists in the treatment of motor complications in advanced Parkinson's disease].

  Neurologia i neurochirurgia polska 20070101

• Use of ropinirole in RLS.

  The Nurse practitioner 20061201

• End-of-dose deterioration in non ergolinic dopamine agonist monotherapy of Parkinson's disease.

  Journal of neurology 20061201

• Development of dyskinesias in a 5-year trial of ropinirole and L-dopa.

  Movement disorders : official journal of the Movement Disorder Society 20061101

• Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial.

  Movement disorders : official journal of the Movement Disorder Society 20061001

• The weight of evidence for ropinirole in restless legs syndrome.

  European journal of neurology 20061001

• Efficacy and tolerability of ropinirole in patients with restless legs syndrome and a baseline IRLS total score > or = 24 points--data from the ropinirole clinical trial programme.

  Current medical research and opinion 20061001

• Ropinirole treatment for restless legs syndrome.

  Drugs of today (Barcelona, Spain : 1998) 20060901

• GSK breached marketing code.

  BMJ (Clinical research ed.) 20060819

• Minimal clinically important change on the unified Parkinson's disease rating scale.

  Movement disorders : official journal of the Movement Disorder Society 20060801

• [Dopamine agonists for treatment of restless leg syndrome].

  Medizinische Monatsschrift fur Pharmazeuten 20060801

• Clinical studies with ropinirole in Parkinson's disease and RLS.

  Journal of neurology 20060801

• A review of the receptor-binding and pharmacokinetic properties of dopamine agonists.

  Clinical therapeutics 20060801

• Association of dopamine agonist use with impulse control disorders in Parkinson disease.

  Archives of neurology 20060701

• Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements.

  Neurology 20060523

• Effect of ropinirole on visuo-motor test in newly diagnosed Parkinson's disease patients.

  Acta neurologica Scandinavica 20060501

• [Ropinirole in the treatment of Parkinson's disease: an update].

  Revista de neurologia 20060501

• Ropinirole hydrochloride, a dopamine agonist.

  Acta crystallographica. Section C, Crystal structure communications 20060501

• Giving legs to restless legs: a case study of how the media helps make people sick.

  PLoS medicine 20060401

• Rapid and sensitive liquid chromatography-mass spectrometry method for determination of ropinirole in human plasma.

  Journal of pharmaceutical and biomedical analysis 20060318

• Psychosis related to ropinirole.

  The American journal of psychiatry 20060301

• Cardiovascular and electrocardiographic effects of the dopamine receptor agonists ropinirole, apomorphine, and PNU-142774E in conscious beagle dogs.

  Journal of cardiovascular pharmacology 20060301

• Effects of terguride, ropinirole, and acetyl-L-carnitine on methamphetamine withdrawal in the rat.

  Pharmacology, biochemistry, and behavior 20060301

• Augmentation of artistic productivity in Parkinson's disease.

  Movement disorders : official journal of the Movement Disorder Society 20060201

• A look back at the most influential drug approvals of 2005.

  The Nurse practitioner 20060201

• Ropinirole (Requip) for restless legs syndrome.

  Obstetrics and gynecology 20060101

• Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial.

  Mayo Clinic proceedings 20060101

• Evaluation of solid-phase sorbents for the analysis of ropinirole in whole blood.

  Journal of analytical toxicology 20060101

• Restless legs syndrome: an update on diagnosis and management.

  Journal of pain & palliative care pharmacotherapy 20060101

• Present and future drug treatment for Parkinson's disease.

  Journal of neurology, neurosurgery, and psychiatry 20051101

• Dopamine D3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons.

  The European journal of neuroscience 20051101

• [Practical experience on improving activities of daily living competence in Parkinson's patients treated with ropinirole. Results of a applied study].

  Der Nervenarzt 20051001

• Pathological gambling in Parkinson's disease.

  The Lancet. Neurology 20051001

• Quelling the quivers caused by restless leg syndrome.

  The Johns Hopkins medical letter health after 50 20051001

• Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy.

  Parkinsonism & related disorders 20050901

• Ropinirole (Requip) for restless legs syndrome.

  The Medical letter on drugs and therapeutics 20050801

• Dopamine type 2 receptor expression and function in rodent sensory neurons projecting to the airways.

  American journal of physiology. Lung cellular and molecular physiology 20050701

• Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.

  Experimental neurology 20050701

• [Ropinirole in the treatment of restless legs].

  Ugeskrift for laeger 20050606

• Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.

  Movement disorders : official journal of the Movement Disorder Society 20050501

• Ropinirole in a child with attention-deficit hyperactivity disorder and restless legs syndrome.

  Pediatric neurology 20050501

• Ropinirole in treatment-resistant depression: a 16-week pilot study.

  Canadian journal of psychiatry. Revue canadienne de psychiatrie 20050501

• Pramipexole, ropinirole, and mania in Parkinson's disease.

  The American journal of psychiatry 20050401

• [Ropinirole treatment of restless legs].

  Ugeskrift for laeger 20050314

• 'Levodopa phobia': a new iatrogenic cause of disability in Parkinson disease.

  Neurology 20050308

• Randomized, double-blind, placebo-controlled, short-term trial of ropinirole in restless legs syndrome.

  Sleep medicine 20050301

• Ropinirole in the treatment of restless legs syndrome.

  Current neurology and neuroscience reports 20050301

• Sleep attacks in patients receiving dopamine-receptor agonists.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20050301

• Dopamine agonists suppress cholinomimetic-induced tremulous jaw movements in an animal model of Parkinsonism: tremorolytic effects of pergolide, ropinirole and CY 208-243.

  Behavioural brain research 20050130

• Ropinirole in the treatment of restless legs syndrome.

  Expert review of neurotherapeutics 20050101

• The reliability, validity and responsiveness of the Restless Legs Syndrome Quality of Life questionnaire (RLSQoL) in a trial population.

  Health and quality of life outcomes 20050101

• Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson's disease.

  Pharmacological reports : PR 20050101

• Ropinirole, a non-ergoline dopamine agonist.

  CNS drug reviews 20050101

• Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study.

  Movement disorders : official journal of the Movement Disorder Society 20041201

• Drug quiets restless legs syndrome.

  Health news (Waltham, Mass.) 20041201

• Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table.

  Movement disorders : official journal of the Movement Disorder Society 20041101

• Predictors of sudden onset of sleep in Parkinson's disease.

  Movement disorders : official journal of the Movement Disorder Society 20041101

• Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease.

  Movement disorders : official journal of the Movement Disorder Society 20041001

• [Restless legs syndrome in a patient with amputation of both legs].

  Revista de neurologia 20040901

• Ropinirole: current status of the studies.

  Journal of neurology 20040901

• Calming restless legs.

  Sleep 20040801

• Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome.

  Sleep 20040801

• Selective blockade of D(3) dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate.

  Experimental neurology 20040701

• Dopamine depletion impairs precursor cell proliferation in Parkinson disease.

  Nature neuroscience 20040701

• Ropinirole versus levodopa in Parkinson's disease.

  Current neurology and neuroscience reports 20040701

• A technique for standardized central analysis of 6-(18)F-fluoro-L-DOPA PET data from a multicenter study.

  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20040701

• Ropinirole therapy for Parkinson's disease.

  Expert review of neurotherapeutics 20040701

• S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: I. Cellular, electrophysiological, and neurochemical profile in comparison with ropinirole.

  The Journal of pharmacology and experimental therapeutics 20040601

• S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole.

  The Journal of pharmacology and experimental therapeutics 20040601

• S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: III. Actions in models of potential antidepressive and anxiolytic activity in comparison with ropinirole.

  The Journal of pharmacology and experimental therapeutics 20040601

• Ropinirole in Gilles de la Tourette syndrome.

  Neurology 20040511

• Ropinirole for restless legs syndrome: a placebo-controlled crossover trial.

  Neurology 20040427

• Severe restless legs syndrome presenting as intractable insomnia.

  Neurology 20040427

• Slowing Parkinson's disease progression: recent dopamine agonist trials.

  Neurology 20040127

• Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia.

  Experimental neurology 20040101

• Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries.

  Journal of neurology, neurosurgery, and psychiatry 20040101

• Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists.

  Archives of neurology 20040101

• Ropinirole as a treatment of restless legs syndrome in patients on chronic hemodialysis: an open randomized crossover trial versus levodopa sustained release.

  Clinical neuropharmacology 20040101

• Ropinirole: for the treatment of restless legs syndrome.

  CNS drugs 20040101

• Ropinirole : a viewpoint by björn w. Walther.

  CNS drugs 20040101

• In vivo iontophoretic administration of ropinirole hydrochloride.

  Journal of pharmaceutical sciences 20031201

• Comparing dopamine agonists in Parkinson's disease.

  Current opinion in neurology 20031201

• Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole.

  Journal of neurochemistry 20031101

• Neuroprotective effects of the novel D3/D2 receptor agonist and antiparkinson agent, S32504, in vitro against 1-methyl-4-phenylpyridinium (MPP+) and in vivo against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a comparison to ropinirole.

  Experimental neurology 20031101

• Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset.

  Movement disorders : official journal of the Movement Disorder Society 20031101

• Rapidly progressive parkinsonism in a self-reported user of ecstasy and other drugs.

  Movement disorders : official journal of the Movement Disorder Society 20031101

• REAL and CALM: what have we learned?

  Movement disorders : official journal of the Movement Disorder Society 20030701

• Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.

  Annals of neurology 20030701

• Dopamine agonist therapy for hyperprolactinemia.

  Clinical obstetrics and gynecology 20030601

• The initial drug treatment of older patients with Parkinson's disease - consider an agonist, but don't demonise dopa.

  Age and ageing 20030501

• [Pseudopheochromocytoma in Parkinson disease and depression].

  Psychiatrische Praxis 20030501

• [Sexual delinquency and Parkinson's disease].

  Der Nervenarzt 20030401

• Sleep attacks--facts and fiction: a critical review.

  Advances in neurology 20030101

• Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease.

  PharmacoEconomics 20030101

• Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study.

  Journal of neurology 20030101

• Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease A short commentary.

  Journal of neurology 20030101

• Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis.

  Drug safety 20030101

• High-dose ropinirole in advanced Parkinson's disease with severe dyskinesias.

  Clinical neuropharmacology 20030101

• Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison.

  Drugs & aging 20030101

• Gabapentin versus ropinirole in the treatment of idiopathic restless legs syndrome.

  Neuropsychobiology 20030101

• A comparison of the progression of early Parkinson's disease in patients started on ropinirole or L-dopa: an 18F-dopa PET study.

  Journal of neural transmission (Vienna, Austria : 1996) 20021201

• Dopamine agonist monotherapy in Parkinson's disease.

  Lancet (London, England) 20021130

• Ropinirole for antidepressant-induced sexual dysfunction.

  International clinical psychopharmacology 20021101

• Do dopamine agonists or levodopa modify Parkinson's disease progression?

  European journal of neurology 20021101

• Levodopa but not ropinirole induces an internalization of D1 dopamine receptors in parkinsonian rats.

  Movement disorders : official journal of the Movement Disorder Society 20021101

• Dosing with ropinirole in a clinical setting.

  Acta neurologica Scandinavica 20021001

• Neuroprotection in idiopathic Parkinson's disease.

  Journal of neurology 20021001

• Practical importance of neuroprotection in Parkinson's disease.

  Journal of neurology 20021001

• Combination of two different dopamine agonists in the management of Parkinson's disease.

  Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20020901

• Two advances in the management of Parkinson disease.

  Cleveland Clinic journal of medicine 20020801

• [The usefulness of dopaminergic drugs in traumatic brain injury].

  Revista de neurologia 20020801

• GSK's Requip slow the loss of dopamine function in Parkinson's disease.

  Aviation, space, and environmental medicine 20020701

• Behavioral and neurochemical effects of dopaminergic drugs in models of brain injury.

  European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20020601

• Ropinirole for the treatment of tremor in early Parkinson's disease.

  European journal of neurology 20020501

• A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa.

  Journal of neural transmission (Vienna, Austria : 1996) 20020401

• Alopecia induced by dopamine agonists.

  Neurology 20020312

• Is it time to abandon functional imaging in the study of neuroprotection?

  Movement disorders : official journal of the Movement Disorder Society 20020301

• Effect of ropinirole on sleep onset: a randomized, placebo-controlled study in healthy volunteers.

  Neurology 20020212

• Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group.

  JAMA 20020101

• DA agonists -- non-ergot derivatives: ropinirole: management of Parkinson's disease.

  Movement disorders : official journal of the Movement Disorder Society 20020101

• [Use of dopamine agonists in the treatment of Parkinson's disease].

  Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20020101

• Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets.

  Neuroscience 20020101

• Ropinirole in restless leg syndrome.

  Missouri medicine 20020101

• [Dopamine agonists situation in Parkinson disease].

  Revista de neurologia 20011201

• Iontophoretic delivery of ropinirole hydrochloride: effect of current density and vehicle formulation.

  Pharmaceutical research 20011201

• Randomized clinical trials with added rescue medication: some approaches to their analysis and interpretation.

  Statistics in medicine 20011030

• Warfarin and ropinirole interaction.

  The Annals of pharmacotherapy 20011001

• Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus).

  Movement disorders : official journal of the Movement Disorder Society 20010701

• Adjunctive dopamine agonists in treatment-resistant bipolar II depression: an open case series.

  Pharmacopsychiatry 20010701

• Literature alert.

  Current neurology and neuroscience reports 20010701

• The frissonnant mutant mouse, a model of dopamino-sensitive, inherited motor syndrome.

  Neurobiology of disease 20010601

• Newer dopamine agonists in the treatment of restless legs syndrome.

  The Annals of pharmacotherapy 20010501

• Antiparkinsonian drugs and 'sleep attacks'.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20010403

• [Parkinson disease: diagnostic and therapeutic criteria].

  Presse medicale (Paris, France : 1983) 20010303

• [Parkinson's disease].

  Presse medicale (Paris, France : 1983) 20010303

• Treatment of early onset Parkinson's disease with ropinirole.

  Journal of neurology, neurosurgery, and psychiatry 20010301

• Possible applications for dopaminergic agents following traumatic brain injury: part 2.

  The Journal of head trauma rehabilitation 20010201

• Efficacy and tolerability of dopamine agonists in a parkinsonian population.

  Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20010201

• The Posturo-Locomotion-Manual Test. A simple method for the characterization of neurological movement disturbances.

  Advances in neurology 20010101

• Molecular mechanism in activation of glutathione system by ropinirole, a selective dopamine D2 agonist.

  Neurochemical research 20010101

• Are dopamine receptor agonists neuroprotective in Parkinson's disease?

  Drugs & aging 20010101

• Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease: a meta-analysis of randomised controlled trials.

  Drug safety 20010101

• High-dose therapy with ropinirole in patients with Parkinson's disease.

  Journal of neural transmission (Vienna, Austria : 1996) 20010101

• Switching from bromocriptine to ropinirole in patients with advanced Parkinson's disease: open label pilot responses to three different dose-ratios.

  Clinical neuropharmacology 20010101

• [Dopaminergic agonists in the treatment of Parkinson's disease].

  Revue medicale de Bruxelles 20001201

• ['Sleep attacks' in Parkinson patients. A side effect of nonergoline dopamine agonists or a class effect of dopamine agonists?].

  Der Nervenarzt 20000801

• Effects of ropinirole on various parkinsonian models in mice, rats, and cynomolgus monkeys.

  Pharmacology, biochemistry, and behavior 20000301

• Clinical pharmacology of dopamine agonists.

  Pharmacotherapy 20000101

• Treatment of Parkinson's disease with ropinirole after pergolide-induced retroperitoneal fibrosis.

  Pharmacotherapy 19991201

• [Ropinirol: a new dopamine agonist in the treatment of Parkinson's disease].

  Neurologia (Barcelona, Spain) 19971001